Scientists at St. Jude Children’s Research Hospital have developed patient-derived tumor organoids and tumor organoid xenografts that accurately reflect the biologic underpinnings of embryonal brain tumors.
A team of scientists from NTU Singapore has developed a new biochip that, when paired with artificial intelligence, can quickly and accurately detect extremely small amounts of microRNAs
McGill University researchers have developed an artificial intelligence tool that can identify small groups of cells most responsible for driving aggressive cancers.
Scientists led by Botond Roska at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) have developed MitoCatch, a system that enables targeted delivery of healthy mitochondria to specific cell types affected by disease.
Researchers from Children’s Hospital of Philadelphia (CHOP) developed a new RNA sequencing strategy that can reveal how genetic variants disrupt gene function and improve the diagnosis of rare diseases.
A natural compound made by Australian bees to seal their hives may help stop scarring in human skin after surgery, injury and burns.
SAN MATEO, Calif. and CHICAGO, April 15, 2026 /PRNewswire/ — Cala®, the bioelectronic medicine leader, today announced U.S. Food and Drug Administration (FDA) clearance of the Cala kIQ® Plus system, the next-generation of its wearable neurostimulation device for action hand tremor in essential tremor (ET) and Parkinson’s disease (PD). Cala kIQ Plus is the latest advancement in TAPS® technology – introducing new therapy modes and adaptive calibration designed to optimize tremor relief and personalize treatment providing patients with an intuitive experience whenever tremor control is needed.
CHICAGO, April 15, 2026 /PRNewswire/ — AIRS Medical today announced that SwiftMR®, an FDA 510(k)-cleared, vendor-neutral MRI image enhancement solution, has received clearance to operate in conjunction with deep learning (DL) reconstruction pipelines from original equipment manufacturers (OEM).
MILFORD, Mass., April 15, 2026 /PRNewswire/ — Waters Corporation (NYSE: WAT) today announced that the BD BACTEC™ FXI Culture System has received CE marking under the European Union’s In Vitro Diagnostic Regulation (IVDR), enabling commercialization in Europe and representing a key milestone in the Company’s clinical microbiology portfolio expansion. The BD BACTEC FXI System is a next-generation, fully automated blood culture system designed to improve the speed, consistency, and accuracy of bloodstream infection diagnostics in modern microbiology laboratories.
AliveCor announced today that it received CE mark for its Kardia 12L electrocardiogram (ECG) system.